The role of steroids in the management of uveitic macular edema

European Journal of Ophthalmology

Volumn 21, Issue SUPPL.6, 2011, Pages 51-55

  de Smet, Marc D ^a,b   Julian, Karina ^a,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSIDAD AUSTRAL   (Argentina)

Author keywords

Macular edema; Steroids; Uveitis

Indexed keywords

DEXAMETHASONE; DRUG CARRIER; FLUOCINOLONE ACETONIDE; GLUCOCORTICOID RECEPTOR; ILUVIEN; PREDNISONE; STEROID; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

CATARACT; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG RESPONSE; DRUG USE; GENE REPRESSION; GLAUCOMA; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RETINA MACULA EDEMA; REVIEW; STEROID THERAPY; TRANSACTIVATION; UNSPECIFIED SIDE EFFECT; UVEITIC MACULAR EDEMA;

ADRENAL CORTEX HORMONES; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS, INTRAOCULAR; INTRAVITREAL INJECTIONS; MACULAR EDEMA; UVEITIS;

EID: 79960980966     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/EJO.2010.6056     Document Type: Review

References (36)

1. de Smet MD, Okada AA. Cystoid macular edema in uveitis. Dev Ophthalmol 2010; 47: 136-47.
2. Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology 2006; 113: 1446-9.
3. Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol 2007; 18: 487-92.
4. Miyake K, Ibaraki N, Goto Y, et al. Escrs Binkhorst lecture 2002: pseudophakic preservative maculopathy. J Cataract Refract Surg 2003; 29: 1800-10.
5. Miyake K, Ota I, Ibaraki N, et al. Enhanced disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema by topical timolol and its preservative in early postoperative pseudophakia. Arch Ophthalmol 2001; 119: 387-94.
6. Catier A, Tadayoni R, Paques M, et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 2005; 140: 200-6.
7. Tran TH, de Smet MD, Bodaghi B, Fardeau C, Cassoux N, Lehoang P. Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography. Br J Ophthalmol 2008; 92: 922-7.
8. Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 2009; 148: 303-9.
9. Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 2004; 111: 946-53.
10. van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol 2006; 142: 192-4.
11. Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behçet's disease. Am J Ophthalmol 2004; 137: 850-7.
12. Curnow SJ, Falciani F, Durrani OM, et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profiles in uveitis. Invest Ophthalmol Vis Sci 2005; 46: 4251-9.
13. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-23.
14. Smoak KA, Cidlowski JA. Mechanisms of glucocorticoid receptor signaling during inflammation. Mech Ageing Dev 2004; 125: 697-706.
15. Oakley RH, Sar M, Cidlowski JA. The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem 1996; 271: 9550-9.
16. Nehmé A, Lobenhofer EK, Stamer WD, Edelman JL. Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics 2009; 2: 58.
17. Edelman JL. Differentiating intraocular glucocorticoids. Ophthalmologica 2010; 224(Suppl 1): 25-30.
18. Narayanan R, Mungcal JK, Kenney MC, Seigel GM, Kuppermann BD. Toxicity of triamcinolone acetonide on retinal neurosensory and pigment epithelial cells. Invest Ophthalmol Vis Sci 2006; 47: 722-8.
19. Chung H, Hwang JJ, Koh JY, Kim JG, Yoon YH. Triamcinolone acetonide-mediated oxidative injury in retinal cell culture: comparison with dexamethasone. Invest Ophthalmol Vis Sci 2007; 48: 5742-9.
20. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin d for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; CD000952.
21. Homik JE, Cranney A, Shea B, et al. A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis. J Rheumatol 1999; 26: 1148-57.
22. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006; 55: 420-6.
23. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol 2008; 53: 139-49.
24. Sallam A, Comer RM, Chang JH, et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol 2008; 126: 200-5.
25. Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005; 112: 1916 e1-7.
26. Byun YS, Park YH. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther 2009; 25: 159-62.
27. Hirano Y, Ito T, Nozaki M, et al. Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes. Jpn J Ophthalmol 2009; 53: 519-22.
28. Venkatesh P, Kumar CS, Abbas Z, Garg S. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul Immunol Inflamm 2008; 16: 217-23.
29. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the standard care vs corticosteroid for retinal vein occlusion (score) study report 5. Arch Ophthalmol 2009; 127: 1101-4.
30. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB III, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 110: 681-6.
31. Driot JY, Novack GD, Rittenhouse KD, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004; 20: 269-75.
32. Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010; 117: 567-75.
33. Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008; 5: 1039-46.
34. Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010; 117: 1393-1399.
35. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007; 125: 309-17.
36. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, shamcontrolled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-46.